A director at Quanterix Corp bought 45,900 shares at 5.419USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will speak in a fireside chat at the on August 13, 2024, at 3:00 p.m., ET. The presentation will be available virtually and participants can register using . The presentation will be available following the conference on Quanterix’s website . To learn more about Quanterix, visit . To learn more about Quanterix’s Simoa® technology, visit: . About Quante...
BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Thursday, August 8, 2024 at 4:30 p.m. E.T., to discuss its second quarter 2024 financial results. Quanterix will issue a press release regarding the second quarter 2024 earnings prior to the conference call on Thursday, August 8, 2024 after the market closes. The press release will be posted on the Quanterix website at . To pre-register for the conference call with a webcast link and for an audio only...
BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today presented new data at the Alzheimer’s Association International Conference (AAIC), supporting a novel multi-marker approach to test for Alzheimer’s disease (AD). For the first time, new data show that applying a combination of AD-relevant biomarkers with p-Tau 217 significantly reduces the intermediate zone of a two-cutoff p-Tau 217 test, while preserving high accuracy above 90%. Recent Alzheimer’s Association criteria for diagnosing Alzheimer’s recomm...
BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended September 30, 2023. Third Quarter Financial Highlights Revenue was $31.3 million, an 18% increase from $26.6 million for the corresponding prior year period. GAAP gross margin was 56.8% as compared to 41.1% for the corresponding prior year period. Non-GAAP gross margin was 48.6% as compared to 34.9% for the corresponding prior year period. Net loss was $7.8 million as compared to $35.1 mill...
BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Eli Lilly and Company, a global healthcare company, presented new data from Lilly’s Phase 2 TRAILBLAZER-ALZ study at AAIC 2021 utilizing Quanterix’ highly sensitive Simoa® technology. The study utilized Quanterix’ HD-X technology and assays to measure P-tau217 (tau phosphorylated at threonine 217), using antibodies developed by Lilly. Lilly reported that the data demonstrates a significant reduction in blood levels of pho...
BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for second quarter 2021 after the close of trading on Aug. 5, 2021. Company management will host a conference call at 4:30pm ET to discuss Quanterix’ financial results and provide a business update. The call will be hosted by Kevin Hrusovsky, Chairman and Chief Executive Officer, Quanterix. Individuals interested in listening to the conference call may do so by dialing 833-686-9351 for domestic calle...
BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its has been used in a worldwide collaborative study of the plasma neurofilament light (NfL) biomarker to evaluate its utility for a range of neurological conditions. Published in , the research marks the most robust effort to date assessing the use of NfL in blood to screen for neurodegeneration as a cause of cognitive symptoms; differentiate among neurodegenerative disorders and distinguish psychiatric disorders; and de...
BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman and Chief Executive Officer, Quanterix, Kevin Hrusovsky will be delivering a virtual presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10th at 3:50pm ET. Attendees can access the public webcast at or by visiting the News & Events page within the Investors section of the Quanterix website at . Replays of the webcast will be available on the Quanterix website for 90 days following the conference. ...
BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced it has named Masoud Toloue to the position of President of Quanterix and Diagnostics, effective June 9, 2021. “We are excited to welcome Masoud to our team at such an important moment for Quanterix,” said Kevin Hrusovsky, Chairman and Chief Executive Officer Quanterix. “We are making important strides in advancing our diagnostic capability and assays, given the NIH RADx funding, our COVID-19 Emergency Use Authorizat...
BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced financial results for the three months ending March 31, 2021. “We made productive advances on our strategic and operational priorities during the first quarter 2021,” said Chairman, Chief Executive Officer and President, Quanterix, Kevin Hrusovsky. “The precision health ecosystem continues to catalyze interest and adoption from healthcare payors, government agencies, academia, and pharmaceutical companies as they ma...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.